Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Hematologic Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Adenoma, Islet Cell 1

Interventions

Abiraterone Acetate 3enzalutamide 2abiraterone 2Prednisone 2sapanisertib 1relugolix 1onvansertib 1apalutamide 1abemaciclib 1Prednisolone 1Methylprednisolone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-Resistant Prostate Cancer × sapanisertib × Clear all
NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡